OakChart

Valion Bio Inc

VBIOHealthcare·Biotechnology·USA·Nano·NASD·Nov 12 • 11:02 AM ET

0.4968-0.0060 (-1.19%)
2026-11-12 17:05 CET
Market cap
1.08 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.10 USD m
Free cash flow, TTM
-5.34 USD m
EPS diluted, TTM
-52.54
P/E
-
Compare

Price

VBIO against its 20, 50 and 200-day averages
2050200earnings
Patternshover a marker to name it
EPS mean, own scalesmoothed
RS 0EPS -6.00Price-6.000.0020.0040.0026.1M52.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26VBIOclose 0.5020-day 0.7350-day 1.70200-day 13.710.50

99.3% under the 52-week high of 67.50 on 11 Dec 2025. 52-week low 0.47 on 5 Nov 2026. Last 15 sessions, 102.5% high to low. This session is unfinished.

Volume 0.10× normal · the line is the 50-bar volume average

Profile

VBIO
52-week range, 0% of the way up
0.4767.50

Valion Bio, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company was founded by Jennifer Ernst and John Claude on September 22, 2016 and is headquartered in San Antonio, TX.

Employees52
IPONov 11, 2021
Beta1.91
ATR, 14d0.18
Rel volume0.10
Short float10.73%
Insider own0.29%
Inst own5.29%

Snapshot

6 groups

Valuation

Index-
Market Cap1.07M
Enterprise Value24.01M
Income-7.51M
Sales0.48M
Book/sh25.57
Cash/sh0.98
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees52
IPONov 11, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S2.22
P/B0.02
P/C0.51
P/FCF-
EV/EBITDA-
EV/Sales50.01
Quick Ratio0.86
Current Ratio1.11
Debt/Eq1.47
LT Debt/Eq1.42
Option/ShortNo / Yes

Earnings

EPS (ttm)-233.18
EPS next Y-
EPS next Q-
EPS this Y-
EPS next Y-
EPS next 5Y-
EPS past 3/5Y83.77% 59.16%
Sales past 3/5Y- -
EPS Y/Y TTM82.22%
Sales Y/Y TTM-49.63%
EPS Q/Q16.56%
Sales Q/Q-100.00%
EarningsMay 14 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own0.29%
Insider Trans0.00%
Inst Own5.29%
Inst Trans5.55%
ROA-156.00%
ROE-178.18%
ROIC-26.10%
Gross Margin-58.51%
Oper. Margin-1548.96%
Profit Margin-1557.26%
SMA20-32.24%
SMA50-70.81%
SMA200-96.38%
Trades-

Technical

Shs Outstand2.16M
Shs Float2.15M
Short Float10.73%
Short Ratio0.12
Short Interest0.23M
52W High67.50 -99.26%
52W Low0.47 5.37%
Volatility9.54% 12.97%
ATR (14)0.18
RSI (14)21.06
Beta1.91
Rel Volume0.10
Avg Volume1.96M
Volume56,037

Performance

Perf Week-1.04%
Perf Month-65.74%
Perf Quarter-89.57%
Perf Half Y-97.87%
Perf YTD-98.63%
Perf Year-99.11%
Perf 3Y-99.90%
Perf 5Y-100.00%
Perf 10Y-
Recom-
Target Price-
Prev Close0.50
Price0.50
Change %-1.19%

Peers

Mkt cap
TickerCompanyMkt cap
LABTLakewood-Amedex Biotherapeutics Inc0.90M
OGENOragenics Inc1.64M
ARTLArtelo Biosciences Inc1.22M
AZTRAzitra Inc3.62M
AZRAzora Therapeutics Inc49.14M
BBLGBone Biologics Corp1.27M
ABVCABVC BioPharma Inc26.16M
COAGHemab Therapeutics Holdings Inc1.79B
TRAXFirst Tracks Biotherapeutics Inc2.02B
AARDAardvark Therapeutics Inc33.92M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Bolton SheryleDirectorApr 15 '26Buy1.0410,00010,40010,000Apr 20 04:02 PM
Valauri Christina RizopoulosDirectorApr 01 '26Buy0.9519,00018,00819,000Apr 02 09:49 AM

News

latest 14 of 200
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird's National Security Conference (ACCESSWIRE)
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results (ACCESSWIRE) -10.83%
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation (ACCESSWIRE) -13.19%
  • Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options (ACCESSWIRE) -10.64%
  • Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value (ACCESSWIRE) -5.88%
  • Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone (ACCESSWIRE) -15.17%
  • With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge (ACCESSWIRE) -6.45%
  • Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand to Support Data Centers (ACCESSWIRE)
  • New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod (ACCESSWIRE)
  • Valion Bio Completes Oral Mucosal Entolimod Formulation, Opening Potential Needle-Free Development Pathway (InvestorsHub)
  • Valion Bio and Shear Kershman Laboratories Successfully Formulate Oral Mucosal Entolimod; Valion Sees Potential for Multi-Fold Expansion of Long-Term Opportunity (ACCESSWIRE)
  • Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions (ACCESSWIRE) +9.64%
  • Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule (ACCESSWIRE)
  • Valion Bio Announces Changes to Management and Board of Directors (ACCESSWIRE) -14.01%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q12026-05-14---53.769---
2025Q32025-11-14---49.1380.15--
2025Q22025-08-14---54.7780.09--
2025Q12025-05-15---62.9650.07--
2024Q32024-11-14-97.750--98.2330.13--
2024Q22024-08-14-136--134.190.14--
2024Q12024-05-15-429.25--428.840.33--
2023Q42024-03-253,859--650.220.36--
2023Q32023-11-14-629-2,975-628.660.280.781
2023Q22023-08-14-2,975-3,400-3,0430.160.631
2023Q12023-05-15-46.750-46.750-4,4690.380.521
2022Q42023-03-31-97.750-131.75-9,8990.400.641
2022Q32022-11-14-114.75-136-11,3480.480.661
2022Q22022-08-15-136-102-13,3310.530.461
2022Q12022-06-17-97.750--9,7990.43--

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-44,200--44,3361.84-
2023FY-4,420--1.18-

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2024Q3S2023-08-231001.261.261.26
2024Q3S2023-08-221001.261.261.26
2024Q3S2023-08-211001.261.261.26
2024Q3S2023-08-201001.261.261.26
2024Q3S2023-08-191001.261.261.26
2024Q3S2023-08-161001.261.261.26
2024Q3S2023-08-151001.261.261.26
2024Q3E2023-08-23100-6.00-6.00-6.00
2024Q3E2023-08-22100-6.00-6.00-6.00
2024Q3E2023-08-21100-6.00-6.00-6.00
2024Q3E2023-08-20100-6.00-6.00-6.00
2024Q3E2023-08-19100-6.00-6.00-6.00
2024Q3E2023-08-16100-6.00-6.00-6.00
2024Q3E2023-08-15100-6.00-6.00-6.00

Estimate history

EPS, annual-19027.25-16692.3-103340.025-44336.425-4418.045-491.967-189.545-233.1755
Period2019202020212022202320242025TTM
EPS, quarterly-134.185-98.235-66.296-62.965-54.778-49.138-53.769-52.537
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26
Sales, annual0.420.861.2571.841.176000.48
Period2019202020212022202320242025TTM
Sales, quarterly0.140.1260.180.070.0860.14600
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26
Shares, annual00000.0030.0220.1010.166
Period2019202020212022202320242025MRQ
Shares, quarterly0.0150.0150.0220.0280.0390.0670.1150.166
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue0.000.000.001.181.841.260.860.42
Cost of Goods Sold Incl. D&A0.360.010.350.901.551.301.090.71
Gross Profit-0.36-0.01-0.350.280.29-0.05-0.23-0.29
Selling, General and Administrative Excl. Other6.077.894.068.5210.395.593.093.35
Research and Development2.353.131.311.651.720.870.770.99
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.42-7.90-4.42-8.24-10.10-5.63-3.32-3.64
Interest Expense0.690.150.000.000.001.820.420.44
Unusual Expense-0.05-0.030.060.000.001.20-0.090.07
Net Income Before Taxes-7.06-7.99-4.47-8.24-10.10-8.49-3.64-4.15
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.06-7.99-4.47-8.24-10.10-8.49-3.64-4.15
Net Income From Continuing Operations-7.06-7.99-4.47-8.24-10.10-8.49-3.64-4.15
Net Income-7.10-8.76-5.66-8.24-10.10-8.49-3.64-4.15
EPS (Recurring)-52.78-189.97-488.31-4,418.05-44,336.52-93,120.56-16,981.22-18,786.22
EPS (Basic, Before Extraordinaries)-52.54-189.54-491.97-4,418.05-44,336.43-103,340.03-16,692.30-19,027.25
EPS (Diluted)-52.54-189.54-491.97-4,418.05-44,336.43-103,340.03-16,692.30-19,027.25
EBITDA-6.07-7.89-4.06-8.06-9.92-5.61-3.31-3.64
Non-Operating Income (Expense)0.010.020.010.000.000.160.010.01
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.130.560.230.270.400.060.080.01
Price To Sales Ratio--2.171.213.3710.78--
Gross Margin-58.51--23.7215.71-3.66-27.09-69.76
Operating Margin-1,548.96---701.11-548.80-448.13-386.16-867.38
Net Margin-1,557.26---701.02-548.70-675.74-423.14-987.62
Shares Outstanding0.170.100.020.000.000.000.000.00
Market Capitalization1.081.083.282.646.1937.7035.30-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q42024Q32024Q2
Total Revenue0.000.000.150.090.070.180.130.14
Cost of Goods Sold Incl. D&A0.360.180.290.030.020.420.080.11
Gross Profit-0.36-0.18-0.140.050.05-0.240.040.03
Selling, General and Administrative Excl. Other6.075.452.341.991.551.301.471.24
Research and Development2.351.670.860.650.330.330.420.30
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-6.42-5.63-2.48-1.93-1.51-1.54-1.43-1.21
Interest Expense0.690.650.000.000.000.000.000.00
Unusual Expense-0.05-0.030.000.000.000.000.000.00
Net Income Before Taxes-7.06-6.22-2.60-1.93-1.50-1.48-1.43-1.27
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.06-6.22-2.60-1.93-1.50-1.48-1.43-1.27
Net Income From Continuing Operations-7.06-6.22-2.60-1.93-1.50-1.48-1.43-1.27
Net Income-7.10-6.20-2.60-1.93-1.50-1.48-1.43-1.27
EPS (Recurring)-52.78-53.97-49.14-54.78-62.96-66.30-98.23-134.19
EPS (Basic, Before Extraordinaries)-52.54-53.77-49.14-54.78-62.96-66.30-98.23-134.19
EPS (Diluted)-52.54-53.77-49.14-54.78-62.96-66.30-98.23-134.19
EBITDA-6.07-5.45-2.48-1.93-1.50-1.27-1.43-1.17
Non-Operating Income (Expense)0.010.02-0.110.000.000.070.00-0.06
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.130.210.140.180.100.060.060.05
Price To Sales Ratio--7.927.922.964.201.611.41
Gross Margin---99.3261.6370.00-132.7834.1320.71
Operating Margin---1,700.68-2,248.84-2,151.43-857.22-1,135.71-861.43
Net Margin---1,778.08-2,245.35-2,145.71-820.56-1,135.71-904.29
Shares Outstanding0.170.120.070.040.030.020.010.01
Market Capitalization1.082.554.814.011.813.281.560.57

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments12.642.003.403.5212.971.042.31
Short Term Receivables0.000.000.170.110.090.050.01
Inventories0.000.000.760.860.430.240.47
Other Current Assets0.360.640.330.230.790.160.17
Total Current Assets13.012.644.654.7214.291.502.97
Net Property, Plant & Equipment12.640.000.470.540.700.020.03
Total Investments and Advances0.000.000.000.000.000.000.00
Intangible Assets5.700.00-----
Deferred Tax Assets0.010.000.100.14---
Other Assets0.260.170.030.620.050.010.02
Total Assets31.622.815.256.0215.041.533.02
Short Term Debt Incl. Current Port. of LT Debt0.000.000.190.160.160.040.00
Accounts Payable0.260.120.711.320.790.370.37
Other Current Liabilities0.380.150.490.390.270.870.28
Total Current Liabilities0.650.271.401.881.221.270.65
Long Term Debt6.450.000.180.370.551.430.00
Provision for Risks Charges0.000.000.000.000.000.000.00
Deferred Tax Liabilities0.010.000.100.14---
Other Liabilities0.340.000.000.000.000.000.00
Total Liabilities7.450.271.672.391.762.710.65
Non-Equity Reserves0.000.000.000.000.000.000.00
Preferred Stock - Carrying Value7.370.000.000.000.000.000.00
Common Equity16.802.543.583.6313.27-1.182.37
Total Shareholders Equity24.172.543.583.6313.27-1.182.37
Accumulated Minority Interest0.000.000.000.000.000.000.00
Total Equity24.172.543.583.6313.27-1.182.37
Total Liabilities & Stockholders Equity31.622.815.256.0215.041.533.02
Book Value Per Share166.26113.801,037.7915,941.1258,059.33-5,403.5310,871.29
Tangible Book Value Per Share109.84113.801,037.7915,941.1258,059.33-5,403.5310,871.28
Full-Time Employees5299161212-
Price to Book Ratio0.021.290.461.072.84-6.09-
Return on Assets-46.44-110.90-148.41-95.91-102.54-159.78-
Return on Equity-59.87-146.20-228.68-119.47-140.45-609.55-
Return on Invested Capital-28.61-223.08-219.49-252.59-61.47-1,421.48-174.95
Quick Ratio20.139.702.782.0511.370.993.83
Current Ratio20.139.703.322.5111.721.174.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income-7.10-8.88-5.66-8.24-10.10-8.49-3.64-4.15
Depreciation0.610.010.350.180.170.020.010.00
Other Funds (Non Cash)0.821.420.770.300.403.260.560.54
Funds from Operations-5.68-7.45-4.53-7.76-9.52-5.21-3.07-3.60
Extraordinary Item0.000.000.000.000.000.000.000.00
Changes in Working Capital0.400.45-1.19-0.750.60-0.400.04-0.07
Cash from Operating Activities-5.28-7.00-5.72-8.51-8.92-5.61-3.03-3.67
Capital Expenditures-0.06-0.580.00-0.12-0.010.000.00-0.03
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.00
Other Uses0.00-0.120.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00
Cash from Investing Activities-0.06-0.700.00-0.12-0.010.000.00-0.03
Cash Dividends Paid0.000.000.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00--
Change in Capital Stock0.2318.524.338.51-0.5314.950.013.84
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00
Sale of Common Pref Stock0.2318.524.338.51-0.5314.950.013.84
Proceedsfrom Stock Options0.2318.414.338.51-0.580.000.013.84
Issuance or Reduction of Debt, Net0.00-0.170.000.000.002.591.751.71
Change in Long Term Debt0.00-0.170.000.000.002.591.751.71
Issuance of Long Term Debt0.000.000.000.000.002.611.771.71
Reduction of Long Term Debt0.00-0.170.000.000.00-0.02-0.020.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.00
Cash from Financing Activities0.2318.354.338.51-0.5317.541.765.55
Net Change in Cash-5.1110.64-1.39-0.12-9.4611.93-1.271.85
Free Cash Flow-5.34-7.04-5.72-8.63-8.93-5.61-3.03-3.70
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q4
Cash & Short Term Investments2.117.213.451.180.672.00
Short Term Receivables0.000.000.020.010.010.07
Inventories0.750.750.000.280.310.32
Other Current Assets0.520.690.270.360.270.25
Total Current Assets3.388.653.741.841.262.64
Net Property, Plant & Equipment22.1822.730.010.120.120.12
Total Investments and Advances0.370.370.000.000.000.00
Intangible Assets5.705.702.242.242.230.00
Deferred Tax Assets-----0.00
Other Assets0.840.770.230.300.170.05
Total Assets32.4738.226.234.513.782.81
Short Term Debt Incl. Current Port. of LT Debt0.530.490.000.000.000.00
Accounts Payable0.640.630.470.230.440.12
Other Current Liabilities1.871.490.170.590.300.15
Total Current Liabilities3.052.620.640.820.740.27
Long Term Debt16.8816.540.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities-----0.00
Other Liabilities0.670.510.000.000.000.00
Total Liabilities20.5919.670.640.820.740.27
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value7.647.490.000.000.000.00
Common Equity4.2511.065.593.693.042.54
Total Shareholders Equity11.8818.555.593.693.042.54
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity11.8818.555.593.693.042.54
Total Liabilities & Stockholders Equity32.4738.226.234.513.782.81
Book Value Per Share25.5796.0384.0595.43107.56113.78
Tangible Book Value Per Share-8.7546.5550.3337.3728.70113.78
Full-Time Employees-----9
Price to Book Ratio0.020.230.861.090.591.29
Return on Assets---156.00-136.50-160.72-140.31
Return on Equity---178.18-160.96-218.77-184.96
Return on Invested Capital-24.70-17.67-46.43-52.37-49.47-58.26
Quick Ratio0.863.025.861.901.298.53
Current Ratio1.113.315.862.241.709.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q32025Q22025Q12024Q4
Net Income-7.10-6.20-2.60-1.93-1.50-1.48
Depreciation0.610.180.000.000.000.27
Other Funds (Non Cash)0.820.840.580.180.100.40
Funds from Operations-5.68-5.18-2.02-1.75-1.40-0.81
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.400.170.02-0.070.51-0.56
Cash from Operating Activities-5.28-5.01-2.00-1.83-0.89-1.36
Capital Expenditures-0.06-0.01-0.01-0.02-0.530.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.06-0.01-0.01-0.02-0.530.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)--0.000.000.000.00
Change in Capital Stock0.23-0.044.272.360.081.18
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.23-0.044.272.360.081.18
Proceedsfrom Stock Options0.23-0.044.272.36-0.031.18
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.23-0.044.272.360.081.18
Net Change in Cash-5.11-5.062.270.52-1.33-0.19
Free Cash Flow-5.34-5.02-2.01-1.83-0.89-1.36

Revenue breakdown

Pharmaceutical Preparations2024: 780.00K
United States2024: 780.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.73%0.2M2.2M1.95M
2026-10-155.37%0.1M2.2M1.66M
2026-09-309.88%0.1M0.9M1.44M
2026-09-154.32%0.0M0.9M387.61K
2026-08-3138.22%0.3M0.9M365.23K
2026-08-147.53%0.1M0.9M233.35K
2026-07-3120.59%0.0M0.2M21.22K
2026-07-156.48%0.0M0.2M13.66K
2026-06-304.96%0.0M0.1M12.60K
2026-06-158.32%0.0M0.1M11.40K
2026-05-294.80%0.0M0.1M12.63K
2026-05-156.52%0.0M0.1M12.31K
2026-04-308.78%0.0M0.1M10.41K
2026-04-152.27%0.0M0.1M8.65K
2026-03-313.29%0.0M0.1M9.22K
2026-03-136.79%0.0M0.1M41.87K
2026-02-271.37%0.0M0.1M35.50K
2026-02-131.89%0.0M0.1M35.90K
2026-01-302.82%0.0M0.1M35.82K
2026-01-153.19%0.0M0.1M35.00K

Option chain

expiry 2026-11-12
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-098-KCurrent report2026-11-06SEC
2026-11-058-KCurrent report2026-10-31SEC
2026-11-028-KCurrent report2026-10-27SEC
2026-10-298-KCurrent report2026-10-28SEC
2026-10-278-KCurrent report2026-10-26SEC
2026-10-268-KCurrent report2026-10-26SEC
2026-10-228-KCurrent report2026-10-21SEC
2026-10-21424B3SEC
2026-10-20EFFECTEffectiveness filing by commission orderSEC
2026-10-20EFFECTEffectiveness filing by commission orderSEC
2026-10-16S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-16DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-12SEC
2026-10-158-KCurrent report2026-10-15SEC
2026-10-148-KCurrent report2026-10-14SEC
2026-10-088-KCurrent report2026-10-07SEC
2026-10-08S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-10-068-KCurrent report2026-10-05SEC
2026-10-05DRSSEC
2026-10-02PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-10-02SEC
2026-10-018-KCurrent report2026-09-30SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-18SEC
2026-09-238-KCurrent report2026-09-17SEC
2026-09-173Initial statement of beneficial ownership of securities2026-08-27SEC
2026-09-173Initial statement of beneficial ownership of securities2026-08-27SEC
2026-09-04SCHEDULE 13G/ASEC
2026-09-03SCHEDULE 13D/ASEC
2026-09-02SCHEDULE 13D/ASEC
2026-08-27SCHEDULE 13D/ASEC
2026-08-278-KCurrent report2026-08-26SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-0428.41K200
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Murchinson Ltd.3.59%
CITADEL ADVISORS LLC2.32%
Sanctuary Advisors, LLC1.91%
Marex Group Ltd1.70%
Virtu Financial LLC1.23%
UBS Group AG1.02%
GEODE CAPITAL MANAGEMENT, LLC0.61%
HRT FINANCIAL LP0.36%
TWO SIGMA SECURITIES, LLC0.32%
Tower Research Capital LLC0.07%

Funds

Fund% owned
Fidelity Extended Market Index Fund0.01%
Blackstone Alternative Multi-Strategy Fund0.00%

OakChart. VBIO. Cached 15 minutes.

Some panels did not load: ratings.